ADMS Adamas Pharmaceuticals Inc.

21.30
+0.18  (1%)
Previous Close 21.12
Open 23.00
Price To book 4.61
Market Cap 479549819
Shares 22,514,076
Volume 2,098,604
Short Ratio 4.22
Av. Daily Volume 898,722

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171079449
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171074032
  3. 8-K - Current report 171014695
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014643
  5. 8-K - Current report 17933988

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data released September 7, 2017.
ADS-4101
Partial onset seizures in patents with epilepsy
Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia

Latest News

  1. Adamas' Parkinson's Drug Cost Is Double Analyst Expectations
  2. Adamas to Host Investor and Analyst Meeting on September 18, 2017
  3. Adamas Announces New Employment Inducement Grant
  4. Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
  5. Could These 2 Biotech Stocks Really Double Your Money?
  6. ETFs with exposure to Adamas Pharmaceuticals, Inc. : August 31, 2017
  7. Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long-acting version of generic
  8. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : August 28, 2017
  9. Today's Research Reports on Stocks to Watch: Adamas Pharmaceuticals and XOMA Corporation
  10. Why Urban Outfitters, Pure Storage, and Adamas Pharmaceuticals Jumped Today
  11. Adamas Pharmaceuticals (ADMS) Stock Soars 41% After FDA Approval
  12. Adamas Skyrockets on FDA Approval for Dyskinesia Treatment - Biotech Movers
  13. 'Date' These Potential Biotech Winners
  14. Why Adamas Pharmaceuticals Inc Stock Skyrocketed Today
  15. Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
  16. GameStop slides, Ulta Beauty falls, Adamas surges, Twitter downgraded
  17. Jackson Hole has the dollar on ‘the edge of a cliff’ — here’s how to play its next move
  18. Janet Yellen's upcoming speech casts shadow on markets
  19. Adamas Pharma shares soar on Parkinson's dyskinesia drug approval

SEC Filings

  1. CT ORDER - Confidential treatment order 171079449
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171074032
  3. 8-K - Current report 171014695
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014643
  5. 8-K - Current report 17933988
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 17884820
  7. 8-K - Current report 17884770
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17832695
  9. 8-K - Current report 17832684
  10. 8-K - Current report 17826335